2023
The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service
Ferrara M, Guloksuz S, Hazan H, Li F, Tek C, Sykes L, Riley S, Keshavan M, Srihari V. The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service. Schizophrenia Research 2023, 260: 198-204. PMID: 37688984, DOI: 10.1016/j.schres.2023.08.005.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis servicesLength of stayUntreated psychosisPsychiatric hospitalizationFirst-episode servicesDuration of hospitalizationIncidence rate ratiosNon-affective psychosisNew Haven areaPoisson regression modelsPatient characteristicsHospitalization ratesRecent onsetMedical recordsHospitalizationEffect of durationNegative binomial regressionSpecialized treatmentPsychosisRate ratioBinomial regressionAdmissionDUPEnrollmentFirst year
2015
Antipsychotic‐induced weight gain in first‐episode psychosis patients: a meta‐analysis of differential effects of antipsychotic medications
Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic‐induced weight gain in first‐episode psychosis patients: a meta‐analysis of differential effects of antipsychotic medications. Early Intervention In Psychiatry 2015, 10: 193-202. PMID: 25962699, PMCID: PMC5589463, DOI: 10.1111/eip.12251.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisAP medicationFEP patientsBody weight gainBMI increaseWeight gainAP useBody mass index (BMI) changeSignificant body weight gainWeight gain riskMore weight gainComprehensive literature searchMean weight gainMeta-regression analysisBaseline weightBMI changeModifiable factorsBMI differencesMedicationsBMI outcomesPlaceboHigher weight gainBMILiterature searchPatientsFirst-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled Trial
Srihari VH, Tek C, Kucukgoncu S, Phutane VH, Breitborde NJ, Pollard J, Ozkan B, Saksa J, Walsh BC, Woods SW. First-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled Trial. Psychiatric Services 2015, 66: 705-712. PMID: 25639994, PMCID: PMC4490067, DOI: 10.1176/appi.ps.201400236.Peer-Reviewed Original ResearchConceptsUsual treatmentSTEP participantsCommunity mental health centerFirst-episode servicesFirst-episode psychosisMental health centersSerious mental illnessInpatient psychiatric unitAntipsychotic exposureAdditional patientsIllness onsetHospital utilizationHealth centersInpatient utilizationPsychiatric hospitalizationMAIN OUTCOMEPsychotic illnessPsychiatric unitPsychotic disordersHospitalizationEarly interventionMental illnessSpecialized treatmentPatientsTranslational research
2013
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
Tek C, Guloksuz S, Srihari VH, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry 2013, 13: 176. PMID: 23805859, PMCID: PMC3702521, DOI: 10.1186/1471-244x-13-176.Peer-Reviewed Original ResearchConceptsSevere mental illnessEfficacy of naltrexoneWeight gainOutcome measurementsHealth problemsMental illnessGreater New Haven areaTumor necrosis factor alphaWeight lossCurrent available medicationsPlacebo-controlled trialHigh-sensitivity CRPOpioid receptor antagonistSecondary outcome measuresSerum lipid profilePrimary outcome measurementBody mass indexD2 receptor blockadeEffects of naltrexoneNovel pharmacological optionsNecrosis factor alphaDoses of naltrexoneMajor health problemRates of obesitySignificant weight lossCardiovascular mortality in schizophrenia: Defining a critical period for prevention
Srihari VH, Phutane VH, Ozkan B, Chwastiak L, Ratliff JC, Woods SW, Tek C. Cardiovascular mortality in schizophrenia: Defining a critical period for prevention. Schizophrenia Research 2013, 146: 64-68. PMID: 23422728, PMCID: PMC3622848, DOI: 10.1016/j.schres.2013.01.014.Peer-Reviewed Original ResearchConceptsPremature cardiovascular mortalityCardiovascular mortalityCardiovascular riskUrban community mental health centerCommunity mental health centerCardiovascular risk estimatesPrior antipsychotic exposureRace-matched peersCardiovascular risk factorsEarly psychosis clinicMental health centersSuch preventive effortsLow-risk categoryCritical periodAntipsychotic exposureBlood pressureMetabolic syndromeObese categoryPsychosis clinicNormal weightPrimary preventionRisk factorsNational HealthHealth centersNutrition Survey
2009
Atypical Antipsychotics for People With Both Schizophrenia and Depression
Furtado VA, Srihari V, Kumar A. Atypical Antipsychotics for People With Both Schizophrenia and Depression. Schizophrenia Bulletin 2009, 35: 297-298. PMID: 19244590, PMCID: PMC2659320, DOI: 10.1093/schbul/sbn188.Peer-Reviewed Original Research
2008
Pulmonary embolism in a patient taking clozapine
Srihari VH, Lee TW. Pulmonary embolism in a patient taking clozapine. The BMJ 2008, 336: 1499. PMID: 18583682, PMCID: PMC2440902, DOI: 10.1136/bmj.39545.690613.47.Peer-Reviewed Original ResearchAtypical antipsychotics for people with both schizophrenia and depression
Furtado V, Srihari V, Kumar A. Atypical antipsychotics for people with both schizophrenia and depression. 2008, 2012: cd005377. PMID: 18254078, PMCID: PMC4171386, DOI: 10.1002/14651858.cd005377.pub2.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsAntipsychotic AgentsChemotherapy, AdjuvantComorbidityDepressionHumansRandomized Controlled Trials as TopicSchizophreniaConceptsAtypical antipsychotic drugsAntipsychotic drugsGroup RegisterRelative riskCochrane Schizophrenia Group's RegisterNew atypical antipsychotic drugHomogenous dichotomous dataRelevant pharmaceutical companiesCo-morbid depressionConfidence intervalsTreatment of peopleLower depression scoresHaloperidol comparisonsTreat basisRandomised trialsAtypical antipsychoticsDATA COLLECTIONClinical trialsHamilton scorePANSS scoresDepression scoresDichotomous dataMean differenceMore trialsSchizophrenia
2007
Resolution of Tardive Dyskinesia After Addition of Aripiprazole to Haloperidol Depot
Kantrowitz JT, Srihari VH, Tek C. Resolution of Tardive Dyskinesia After Addition of Aripiprazole to Haloperidol Depot. Journal Of Clinical Psychopharmacology 2007, 27: 525-526. PMID: 17873695, DOI: 10.1097/jcp.0b013e31814f3002.Peer-Reviewed Original Research